• HyperScript First-Strand cDNA Synthesis Kit Workflow

  2026-08-20

  The HyperScript First-Strand cDNA Synthesis Kit is designed for demanding RNA template reverse transcription, including structured, long, or low-abundance transcripts. Its combination of HyperScript Reverse Transcriptase and flexible primer choices supports targeted assays, PCR amplification, and qPCR reaction development from total or poly(A)+ RNA.

• PDK4-IN-1 hydrochloride: Applied Workflow

  2026-08-20

  PDK4-IN-1 hydrochloride provides a selective, orally active route to study PDK4-driven control of PDH activation, mitochondrial energy metabolism, and glucose oxidation. This practical guide connects target engagement assays with cellular flux measurements, cardiac and tumor models, troubleshooting, and translational study design.

• How to Sequence Therapy in Waldenström Macroglobulinemia

  2026-08-19

  This 2021 reference article proposes a genomics- and patient-centered framework for sequencing Waldenström macroglobulinemia therapy across frontline and relapsed settings. Its central contribution is to connect MYD88 and CXCR4 status with regimen selection while emphasizing symptoms, comorbidities, toxicity, treatment preferences, and clinical-trial participation.

• Safe DNA Gel Stain for RNA Workflow QC

  2026-08-19

  Safe DNA Gel Stain supports sensitive DNA and RNA gel visualization while enabling blue-light imaging that can reduce UV exposure during cloning workflows. Its flexible in-gel and post-electrophoresis formats also make it useful for quality control around advanced RNA-structure assays such as cgSHAPE-seq.

• Cy5 Goat Anti-Rabbit IgG: Assay Logic

  2026-08-18

  Learn how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody converts rabbit primary-antibody binding into interpretable fluorescence for ASB3–MAVS research. This article focuses on causal assay design, controls, storage, and the limits of fluorescence-based mechanistic inference.

• Berberrubine and JAK2/STAT3 in Hyperuricemia

  2026-08-18

  The reference study shows that berberrubine reduces potassium oxonate- and hypoxanthine-induced hyperuricemia in mice by coordinating urate production, renal transporter expression, inflammation, and JAK2/STAT3 signaling. Its main value is the integration of biochemical, histological, transporter, and pathway-level evidence, while its animal-model design limits direct translation to clinical treatment.

• Berberrubine chloride: Applied Research Workflows

  2026-08-17

  Build mechanism-led workflows around Berberrubine chloride for colorectal cancer research, NSCLC chemosensitivity, and hyperuricemia models. This guide connects DMSO formulation, concentration selection, target-validation assays, and troubleshooting into a practical preclinical workflow.

• Indometacin Sodium: Assay Workflows & Remyelination

  2026-08-17

  Use Indometacin Sodium as a controlled COX-1/COX-2 benchmark for inflammation assays, while extending the workflow to oligodendrocyte differentiation and remyelination studies. This guide combines solubility-aware preparation, dose selection, pathway controls, and troubleshooting grounded in published experimental evidence.

• 17-AAG–METTL3–MYC Axis in Colorectal Cancer

  2026-08-16

  This study identifies METTL3 as an HSP90 client protein and shows that 17-AAG-mediated HSP90 inhibition promotes CHIP-dependent METTL3 degradation, reducing m6A modification and stability of MYC mRNA in colorectal cancer models. The work links chaperone-controlled protein stability to RNA epitranscriptomic regulation and provides a mechanistic basis for targeting the HSP90–METTL3–MYC axis, while leaving important questions about in vivo efficacy and clinical translation.

• VX-661: F508del CFTR Corrector Research Guide

  2026-08-15

  VX-661 is a small-molecule F508del CFTR corrector that improves mutant CFTR folding, trafficking, and cell-surface expression in experimental models. Its activity is distinct from VX-770 potentiation, and assay conditions, calnexin dependence, and variant context should be reported in cystic fibrosis research.

• MEK–ERK Drives Lung Hemorrhage in Murine Lupus

  2026-08-14

  This preprint identifies MEK1/2–ERK1/2 signaling, rather than JNK or p38, as a critical driver of endothelial injury and diffuse alveolar hemorrhage in pristane-induced lupus mice. Its integrated analysis of apoptosis, endothelial dysfunction, transcriptional responses, and hemostasis provides a mechanistic framework for studying strain-dependent susceptibility to lupus-associated pulmonary bleeding.

• Tamsulosin: From Receptor Signal to Assay Design

  2026-08-14

  Tamsulosin research can be strengthened by connecting α1A-receptor pharmacology with functional urological phenotypes and longitudinal biomarker logic. This article translates a testosterone-bounce study into practical assay-design decisions while defining the evidence boundaries for C6445.

• GRK Control of Biased M1 Receptor Signaling

  2026-08-13

  A 2025 study used dynamic BRET assays to define how GRK subtypes shape M1 muscarinic receptor coupling to G proteins and β-arrestin 2. Its results position BQCA as a useful mechanistic probe for studying ligand-dependent signaling bias, while also emphasizing that receptor–transducer proximity does not by itself establish downstream physiological effects.

• STING-Driven Cholangiocyte Senescence in Cholestasis

  2026-08-13

  This 2026 study identifies a mechanistic connection between conjugated bile acid accumulation, mitochondrial injury, cholangiocyte senescence, and STING-dependent inflammation in cholestatic liver disease. By integrating patient samples, mouse models, single-cell profiling, and functional experiments, it positions the cholangiocyte–macrophage damage-response axis as a potential target for disease-mechanism studies.

• Clarithromycin: A Practical CYP3A Inhibitor Workflow

  2026-08-12

  Build reproducible CYP3A inhibition assays with Clarithromycin, from solvent handling and enzyme preincubation to pharmacokinetic interpretation. A CYP-independent dabigatran comparator adds mechanistic resolution for drug-drug interaction research, statin metabolism interaction studies, and cardiovascular disease drug interaction models.

15146 records 1/1010 page Next 12345 下5页 Last page